Ticagrelor, acting as a reversible platelet aggregation inhibitor of P2Y12 receptors (P2Y12R), is regarded as one of the first-line antiplatelet drugs for acute cardiovascular diseases. Though the probability of ticagrelor resistance is much lower than that of clopidogrel, there have been recent reports of ticagrelor resistance. In this review, we summarized the clinical application of ticagrelor and then presented the criteria and current status of ticagrelor resistance. We further discussed the potential mechanisms for ticagrelor resistance in terms of drug absorption, metabolism, and receptor action. In conclusion, the incidences of ticagrelor resistance fluctuated between 0 and 20%, and possible mechanisms mainly arose from its absorption and receptor action. Specifically, a variety of factors, such as the drug form of ticagrelor, gut microecology, and the expression and function of P-glycoprotein (P-gp) and P2Y12R, have been shown to be associated with ticagrelor resistance. The exact mechanisms of ticagrelor resistance warrant further exploration, which may contribute to the diagnosis and treatment of ticagrelor resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918175 | PMC |
| http://dx.doi.org/10.3390/jcm12031149 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Platelet-Function-Monitoring-Guided Therapy After Emergent Carotid Artery Stenting.
J Clin Med
November 2024
Cerebrovascular Research Unit Rigshospitalet, Department of Neurology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Antiplatelet therapy after emergent carotid stenting (eCAS) represents a challenge in balancing the risk of intracerebral hemorrhages (ICHs) and in-stent thrombosis (IST). Post-procedural platelet function monitoring may guide antiplatelet therapy and could potentially improve outcomes due to fewer post-procedural complications. Consecutive eCAS patients (2019-2021) were included in a single-center retrospective observational study.
View Article and Find Full Text PDFThromboelastography with Platelet Mapping to Optimize Surgical Timing in Coronary Artery Bypass Grafting Patients on P2Y12 Receptor Blockers Therapy.
Braz J Cardiovasc Surg
October 2024
Anesthesia and Intensive Care Unit II, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Puglia, Italy.
Article Synopsis
- A study was conducted to evaluate preoperative platelet function in patients receiving antiplatelet drugs before coronary artery bypass grafting (CABG), aiming to shorten surgical wait times.* -
- The research involved 48 patients on various P2Y12 receptor blockers and assessed their platelet response using thromboelastography-platelet mapping, revealing resistance rates of 25% for clopidogrel, 33% for ticagrelor, and 33% for prasugrel.* -
- Findings suggested that identifying resistance to these medications can significantly reduce CABG waiting times compared to existing guidelines, thereby minimizing potential life-threatening delays.*
Potential roles for eNOS and NrF₂ /HO-1 signaling in the ameliorative effect of lixisenatide on diabetes-induced kidney injury in rats and its amplification by ticagrelor co-administration.
Pharmazie
October 2024
Department of Pharmacology and Toxicology, Faculty of Pharmacy, South Valley University, Qena, 83523, Egypt.
Article Synopsis
- The study investigates the protective effects of lixisenatide (LX) and ticagrelor (TC) on diabetic nephropathy in rats with type 2 diabetes mellitus (T2DM), highlighting their antioxidant and anti-inflammatory properties.
- Researchers induced T2DM in rats through a high-fat diet and an injection of streptozotocin, then treated them with LX, TC, or both over 4 weeks.
- The results showed that both drugs improved kidney function and reduced injury markers, with the combined treatment yielding the most significant benefits by activating key antioxidant pathways and reducing inflammation in kidney tissues.*
Ticagrelor and Statins: Dangerous Liaisons?
Cardiovasc Drugs Ther
December 2024
Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Viale Pieraccini 6, Florence, Italy.
Polypharmacy is often necessary in complex, chronic, comorbid and cardiovascular patients and is a known risk factor for potential drug-drug interaction (DDI) that can cause adverse reactions (toxicity or therapeutic failure). Anti-thrombotic drugs (largely low-dose aspirin and a platelet P2Y12 receptor inhibitor) and statins are among the most co-administered drugs in cardiovascular patients. Ticagrelor is a selective antagonist of the platelet P2Y12-receptor, highly effective in inhibiting platelet aggregation and bio-transformed by the CYP3A4 and substrate of transporters, such as the breast cancer resistance protein (BCRP).
View Article and Find Full Text PDFTicagrelor alters the membrane of and enhances the activity of vancomycin and daptomycin without eliciting cross-resistance.
mBio
October 2024
Laboratory of Cardiology, GIGA Research Institute, University of Liège, Liège, Belgium.
Infections with multidrug-resistant bacteria pose a major healthcare problem which urges the need for novel treatment options. Besides its potent antiplatelet properties, ticagrelor has antibacterial activity against Gram-positive bacteria, including methicillin- and vancomycin-resistant (MRSA and VRSA). Several retrospective studies in cardiovascular patients support an antibacterial effect of this drug which is not related to its antiplatelet activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!